Stroke drug study halted early: new dosing regimen tested in 17 patients
Disease control
Terminated
This study aimed to find the best dose of MCI-186 for people who had an acute ischemic stroke. It compared a new way of giving the drug (a bolus followed by continuous infusion) with the standard twice-daily dosing for 14 days. The trial was terminated early and included only 17 …
Phase: PHASE2 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC